ClinicalTrials.gg
CompletedNCT03886688Updated Apr 13, 2023

HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers

A Phase 1 interventional study of HEC53856 and placebo in Healthy, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-13.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

To evaluate the safety, tolerability and pharmacokinetics of HEC53856 after single or multiple oral administration, as well as the food effect on the pharmacokinetics, in healthy non-elderly subjects.

Read the detailed description

This is a Phase I, Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Tolerability and Pharmacokinetics of HEC53856 capsule in Healthy Adult Subjects. The study consists of three parts, single dose ascending, multiple dose ascending and food effect testing. Within each part participants will be randomized to either drug or placebo.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy volunteers
  • age: 18-45 years old(18 and 45 included).
  • B.W. male> 50kg, female> 45kg, - 18-28 kg/m\^2
  • females must not be pregnant and males and females must agree to use during the study.
  • able to give and comply with protocol.
  • physical examination and vital signs without abnormalities.
  • agree to use contraceptive methods after informed consent acquisition through 6 months after the last administration of the study drug.

Exclusion criteria

Exclusion Criteria:

  • history or presence of severe gastrointestinal or systemic disorders (e.g. respiratory, endocrine, immunological, dermatological, neurological, psychiatric, renal, hepatic disease etc.)
  • history or presence of significant alcoholism or drug abuse within past 5 years
  • smokers, who smoke more than 5 cigarettes per day within past 3 months
  • heavy drinker, namely alcohol consumption are 14 units per week (1 unit = 285 mL of beer, or 25 mL of strong wine, or 100 mL of grape wine);
  • donated blood or massive blood loss within 3 months before screening (>450 mL)
  • have any disease that increases the risk of bleeding or thrombus, such as acute gastritis or stomach and duodenal ulcers;
  • laboratory findings during screening
  • history or presence of clinically significant abnormalities
  • participated in drug research study within past 3 months
  • used over-the-counter/ prescription/ herbal medications/ supplements within past 14 days.
  • Strenuous activity (as assessed by the investigator) is prohibited from 2 weeks prior to admission until discharge from the unit.
  • female in pregnancy or lactation.
  • viral hepatitis(including CHB and CHC)and positive test result of anti- Ab or syphilis.
  • the investigator believes that the one should not be included
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    single ascending

    Drug or placebo, oral, fast, single dose ascending

    Drug: HEC53856 · Drug: placebo

  • Experimental
    multiple ascending

    Drug or placebo, oral, fast, multiple dose ascending

    Drug: HEC53856 · Drug: placebo

  • Experimental
    Food Effect

    Drug or placebo, oral, fed or fast, single dose

    Drug: HEC53856 · Drug: placebo

Interventions

  • oral administration

    Also known as: HEC53856 capsule

  • Drugplacebo

    oral administration

    Also known as: HEC53856 matching placebo capsule

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events [Safety and Tolerability]

    To assess the safety and tolerability by incidence of treatment-emergent adverse events after a single dose or multiple doses of HEC53856 capsule

    Time frame: Up to Day 10 after last dose

Secondary outcomes

  1. AUC0-t

    Area under the concentration versus time curve (AUC) from time zero to the time of the last quantifiable concentration

    Time frame: Up to 96 hours after dosing

  2. Cmax

    Maximum observed plasma concentration

    Time frame: Up to 96 hours after dosing

  3. Tmax

    Time of the maximum observed plasma concentration

    Time frame: Up to 96 hours after dosing

  4. T T½

    Apparent terminal elimination half-life

    Time frame: Up to 96 hours after dosing

Other outcomes

  1. Vz/F

    Apparent volume of distribution

    Time frame: Up to 96 hours after dosing

07

Study locations

1 site
  • First Hospital of Jilin University
    Changchun, Jilin 130000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Jan 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 22, 2019
StartActual
May 14, 2019
Primary completionActual
Jan 1, 2020
CompletionActual
Jan 1, 2020
Last update
Apr 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03886688
Responsible party
Sponsor
First posted
Mar 22, 2019
Start date
May 14, 2019
Primary completion
Jan 1, 2020
Completion
Jan 1, 2020
Last update
Apr 13, 2023

Study contacts

Ding Yanhua, Doctor
principal investigator · The First Hospital of Jilin University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HEC53856

Start the discussion